Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7450860 | 0.92 | MAOB (0.54) | MAOBALOX5LMNACYP1A2PTGS1 | |
| SCHEMBL24619909 | 0.87 | LTA4H (0.51) | MAOBRAB9A | |
| SCHEMBL8512404 | 0.87 | MAOB (0.56) | MAOBALOX5LMNACYP1A2PTGS1 | |
| SCHEMBL9369289 | 0.84 | RAB9A (0.49) | MAOBALOX5RAB9A | |
| SCHEMBL21675841 | 0.83 | MAOB (0.62) | MAOBMAOARAB9A | |
| SCHEMBL6119008 | 0.83 | MAOB (0.68) | MAOBMAOA | |
| SCHEMBL189829 | 0.82 | MAOB (0.53) | MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL1773163 | 0.82 | MAOB (0.49) | MAOBMAOA | |
| SCHEMBL24628664 | 0.81 | APP (0.45) | MAOBLMNAMAPTRAB9A | |
| SCHEMBL6582384 | 0.81 | CYP1A2 (0.56) | MAOBALOX5LMNACYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115943145-B | Pyrazolopyrimidine compounds as ATR kinase inhibitors | BEIJING TIDE PHARMACEUTICAL CO.,LTD. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12595263-B2 | Pyrazolopyrimidine compound used as ATR kinase inhibitor | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260015323-A1 | PIPERIDINE COMPOUNDS | TELO THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-4587435-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS AND DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2025-07-23 | — | — | EP | disclosed |
| US-12338253-B2 | Nitrogen-containing polycyclic fused ring compound, pharmaceutical composition thereof, preparation method therefor and use thereof | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2025-06-24 | — | — | US | disclosed |
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-12-05 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| US-5132328-A | Lipoxygenase inhibitors as antiinflammatory agents or antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-21 | — | — | US | disclosed |
| US-5098930-A | Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-24 | — | — | US | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| CN-1046903-A | Process for preparing heterocyclic ether derivatives | ICI PLC (GB) | 1990-11-14 | — | — | CN | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385680-A2 | Heterocyclic ethers as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
| EP-0375368-A2 | Alcohol and ether derivatives | ZENECA LIMITED (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338253-B2 | Nitrogen-containing polycyclic fused ring compound, pharmaceutical composition thereof, preparation method therefor and use thereof | RET, WEE1, TIAM1 | MAOB 2907/4885ALOX5 3080/4885LMNA 2939/4885 |
| US-20260015323-A1 | PIPERIDINE COMPOUNDS | XPO1, NR0B1, NR2E1 | MAOB 1974/4885ALOX5 3315/4885LMNA 1245/4885 |
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | MAOB 903/4885ALOX5 3690/4885LMNA 2140/4885 |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | MAOB 1865/4885ALOX5 2545/4885LMNA 1919/4885 |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | SLC5A2, SLC5A1, GPR119 | MAOB 739/4885ALOX5 3461/4885LMNA 2131/4885 |
| US-12595263-B2 | Pyrazolopyrimidine compound used as ATR kinase inhibitor | ATR, CHEK1, ATRIP | MAOB 2919/4885ALOX5 4493/4885LMNA 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.